Citations

Clear

3942 citation(s) found for "To, Van".

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Westin, Jason R. , Locke, Frederick L. , Dickinson, Michael , Ghobadi, Armin , Elsawy, Mahmoud , Meerten, Tom van , Miklos, David B. , Ulrickson, Matthew L. , Perales, Miguel‐Angel , Farooq, Umar , Leslie, Lori A. , Kersten, Marie José , Jacobson, Caron A. , Pagel, John M. , Wulf, Gerald , Johnston, Patrick B. , Rapoport, Aaron P. , Du, Linqiu , Vardhanabhuti, Saran , Filosto, Simone , Shah, Jina , Snider, Julia Thornton , Cheng, Paul , To, Christina , Oluwole, Olalekan O. , Sureda, Anna , van Meerten, Tom , Wannesson, Luciano , Leslie, Lori , Kersten, Marie José , Jacobson, Caron A , Pagel, John M , Wulf, Gerald , Johnston, Patrick , Rapoport, Aaron P , Du, Linqiu , Vardhanabhuti, Saran , Filosto, Simone , Shah, Jina , Snider, Julia T , Cheng, Paul , To, Christina , Oluwole, Olalekan O , Sureda, Anna , Farooq, Umar , Perales, Miguel-Angel , Miklos, David B , Westin, Jason R , Dickinson, Michael , Ghobadi, Armin , Locke, Frederick L

Mayo Clinic

Clinical Cancer Research | March 31, 2023 | Volume: 29 | Issue: 10 | Pages: 1894-1905

10.1158/1078-0432.ccr-22-3136 | PMID 36999993 Get It

Abstract Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7. Patients and Methods: Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2–3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs). Results: Fifty-one and 58 patients aged ≥65 years were randomized to axi-cel and SOC, respectively. Median EFS was greater with axi-cel versus SOC (21.5 vs. 2.5 months; median follow-up: 24.3 months; HR, 0.276; descriptive P < 0.0001). Objective response rate was higher with axi-cel versus SOC (88% vs. 52%; OR, 8.81; descriptive P < 0.0001; complete response rate: 75% vs. 33%). Grade ≥3 adverse events occurred in 94% of axi-cel and 82% of SOC patients. No grade 5 cytokine release syndrome or neurologic events occurred. In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum inflammatory profile were comparable in patients ≥65 and <65 years. Conclusions: Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients ≥65 years with R/R LBCL.
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma
Heater, Natalie Knox , Okuno, Scott H. , Attia, Steven , Seetharam, ­Mahesh , Yoon, Janet, Chawla, Sant P. , Milhem, Mohammed , Monga, Varun , Skubitz, Keith M. , Charlson, John A. , Hirbe, Angela C. , Weiss, Mia C. , Tine, Brian A. Van , Agulnik, Mark , Robinson, Steven, Monga, Varun , Skubitz, Keith , Hirbe, Angela C , Van Tine, Brian A , Agulnik, Mark , Milhem, Mohammed M , Robinson, Steven I. , Siontis, Brittany L.

Mayo Clinic

Journal of Clinical Medicine | March 29, 2023 | Volume: 12 | Issue: 7 | Pages: 2561

10.3390/jcm12072561 | PMID 37048645 Get It

The treatment of sarcoma necessitates a collaborative approach, given its rarity and complex management. At a single institution, multidisciplinary teams of specialists determine and execute treatment plans involving surgical, radiation, and medical management. Treatment guidelines for systemic therapies in advanced or nonresectable soft tissue sarcoma have advanced in recent years as new immunotherapies and targeted therapies become available. Collaboration between institutions is necessary to facilitate accrual to clinical trials. Here, we describe the success of the Midwest Sarcoma Trials Partnership (MWSTP) in creating a network encompassing large academic centers and local community sites. We propose a new model utilizing online platforms to expand the reach of clinical expertise for the treatment of advanced soft tissue sarcoma.
Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)
Boughey, Judy C. , Rosenkranz, Kari M. , McCall, Linda, Haffty, Bruce G. , Cuttino, Laurie W., Kubicky, Charlotte Dai, Le‐Petross, Huong T. , Giuliano, Armando E. , Hahn, Olwen, Boughey, JC , Haffty, Bruce G , Hunt, KK , Carey, Lisa A , Partridge, Ann H , Ballman, Karla V. , Zee, Kimberly J. Van , Hunt, Kelly K. , Carey, Lisa A. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 28, 2023 | Volume: 41 | Issue: 17 | Pages: 3184-3193

10.1200/jco.22.02553 | PMID 36977292 Get It

PURPOSE Breast-conserving therapy (BCT) is the preferred treatment for unifocal breast cancer (BC). The oncologic safety of BCT for multiple ipsilateral breast cancer (MIBC) has not been demonstrated in a prospective study. ACOSOG Z11102 (Alliance) is a phase II, single-arm, prospective trial designed to evaluate oncologic outcomes in patients undergoing BCT for MIBC. PATIENTS AND METHODS Women age 40 years and older with two to three foci of biopsy-proven cN0-1 BC were eligible. Patients underwent lumpectomies with negative margins followed by whole breast radiation with boost to all lumpectomy beds. The primary end point was cumulative incidence of local recurrence (LR) at 5 years with an a priori rate of clinical acceptability of <8%. RESULTS Among 270 women enrolled between November 2012 and August 2016, there were 204 eligible patients who underwent protocol-directed BCT. The median age was 61 years (range, 40-87 years). At a median follow-up of 66.4 months (range, 1.3-90.6 months), six patients developed LR for an estimated 5-year cumulative incidence of LR of 3.1% (95% CI, 1.3 to 6.4). Patient age, number of sites of preoperative biopsy–proven BC, estrogen receptor status and human epidermal growth factor receptor 2 status, and pathologic T and N categories were not associated with LR risk. Exploratory analysis showed that the 5-year LR rate in patients without preoperative magnetic resonance imaging (MRI; n = 15) was 22.6% compared with 1.7% in patients with a preoperative MRI (n = 189; P = .002). CONCLUSION The Z11102 clinical trial demonstrates that breast-conserving surgery with adjuvant radiation that includes lumpectomy site boosts yields an acceptably low 5-year LR rate for MIBC. This evidence supports BCT as a reasonable surgical option for women with two to three ipsilateral foci, particularly among patients with disease evaluated with preoperative breast MRI.
APOE and immunity: Research highlights
Kloske, Courtney M. , Barnum, Christopher J. , Batista, André F., Bradshaw, Elizabeth M. , Bu, Guojun , Dennison, Jessica , Gearon, Mary D, Goate, Alison , Haass, Christian , Hu, William T. , Huggins, Lenique , Jones, Nahdia S. , Liddelow, Shane A. , Marsh, Samuel E. , Petersen, Melissa, Piña‐Escudero, Stefanie Danielle , Reiman, Eric M. , Sexton, Claire E. , TCW, Julia , Wallings, Rebecca L. , Weninger, Stacie, Wharton, Whitney , Wishard, Tyler J. , Worley, Susan, Carrillo, María C. , Sexton, Claire , Bu, Guojun , Goate, Alison M , Hu, William T. , Brickman, Adam M. , Heneka, Michael T. , Koldamova, Radosveta P. , Lemere, Cynthia Ann , Marcora, Edoardo , Nielsen, Henrietta M. , Petersen, Kellen K. , Petersen, Melissa , Qiu, Wei Qiao , Quiroz, Yakeel T. , Tansey, Malú G. , Teunissen, Charlotte E. , Tijms, Betty M. , Kant, Rik van der , Wilcock, Donna M. , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | March 28, 2023 | Volume: 19 | Issue: 6 | Pages: 2677-2696

10.1002/alz.13020 | PMID 36975090 Get It

AbstractINTRODUCTIONAt the Alzheimer's Association's APOE and Immunity virtual conference, held in October 2021, leading neuroscience experts shared recent research advances on and inspiring insights into the various roles that both the apolipoprotein E gene (APOE) and facets of immunity play in neurodegenerative diseases, including Alzheimer's disease and other dementias.METHODSThe meeting brought together more than 1200 registered attendees from 62 different countries, representing the realms of academia and industry.RESULTSDuring the 4‐day meeting, presenters illuminated aspects of the cross‐talk between APOE and immunity, with a focus on the roles of microglia, triggering receptor expressed on myeloid cells 2 (TREM2), and components of inflammation (e.g., tumor necrosis factor α [TNFα]).DISCUSSIONThis manuscript emphasizes the importance of diversity in current and future research and presents an integrated view of innate immune functions in Alzheimer's disease as well as related promising directions in drug development.
Safety and Efficacy With Pulsed Field Ablation: Having the Cake and Eating It Too
Zyl, Martin van , Asirvatham, Samuel J. , van Zyl, Martin , Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | March 27, 2023 | Volume: 16 | Issue: 4 | Pages: No page available

10.1161/circep.123.011955 | PMID 36970977 Get It

Prevention of the Vertical Transmission of HIV; A Recap of the Journey so Far
Cárdenas, María C. , Farnan, Sheila, Hamel, Benjamin , Plazas, Maria C. Mejia , Sintim-Aboagye, Elise, Littlefield, Dawn, Punia, Sohan, Enninga, Elizabeth Ann L. , Temesgen, Zelalem , Theiler, Regan N. , Gray, Clive M. , Chakraborty, Rana , Cardenas, Maria Camila, Mejia Plazas, Maria Camila, Littlefield, Dawn R, Behl, Supriya, Enninga, Elizabeth Ann L , Theiler, Regan , Gray, Clive M , Chakraborty, Rana , Behl, Supriya , Johnson, Erica L.

Mayo Clinic

Viruses | March 27, 2023 | Volume: 15 | Issue: 4 | Pages: 849

10.3390/v15040849 | PMID 37112830 Get It

In 1989, one in four (25%) infants born to women living with HIV were infected; by the age of 2 years, there was 25% mortality among them due to HIV. These and other pieces of data prompted the development of interventions to offset vertical transmission, including the landmark Pediatric AIDS Clinical Trial Group Study (PACTG 076) in 1994. This study reported a 67.5% reduction in perinatal HIV transmission with prophylactic antenatal, intrapartum, and postnatal zidovudine. Numerous studies since then have provided compelling evidence to further optimize interventions, such that annual transmission rates of 0% are now reported by many health departments in the US and elimination has been validated in several countries around the world. Despite this success, the elimination of HIV’s vertical transmission on the global scale remains a work in progress, limited by socioeconomic factors such as the prohibitive cost of antiretrovirals. Here, we review some of the key trials underpinning the development of guidelines in the US as well as globally, and discuss the evidence through a historic lens.
Intraoperative Red Blood Cell Transfusion and Primary Graft Dysfunction After Lung Transplantation
Loor, Gabriel , Bottiger, Brandi , Ius, F. , Hartwig, Matthew G. , Daoud, Daoud, Zhang, Qianzi, Villavicencio-Theoduloz, M., Chandrashekaran, Satish, Machuca, Tiago , Raemdonck, Dirk Van , Neyrinck, Arne , Toyoda, Yoshiya , Kashem, Mohammed A. , Huddleston, Stephen J. , Ryssel, N., Sánchez, Pablo G. , Villavicencio-Theoduloz, Mauricio A, Van Raemdonck, Dirk , Huddleston, Stephen , Bottiger, Brandi Anne , Subramaniam, Kathirvel , Chan, Ernest G. , Wei, Qi , Osho, Asishana A. , Ryssel, N.

Mayo Clinic

Transplantation | March 24, 2023 | Volume: 107 | Issue: 7 | Pages: 1573-1579

10.1097/tp.0000000000004545 | PMID 36959119 Get It

Background. In this international, multicenter study of patients undergoing lung transplantation (LT), we explored the association between the amount of intraoperative packed red blood cell (PRBC) transfusion and occurrence of primary graft dysfunction (PGD) and associated outcomes. Methods. The Extracorporeal Life Support in LT Registry includes data on LT recipients from 9 high-volume (>40 transplants/y) transplant centers (2 from Europe, 7 from the United States). Adult patients who underwent bilateral orthotopic lung transplant from January 2016 to January 2020 were included. The primary outcome of interest was the occurrence of grade 3 PGD in the first 72 h after LT. Results. We included 729 patients who underwent bilateral orthotopic lung transplant between January 2016 and November 2020. LT recipient population tertiles based on the amount of intraoperative PRBC transfusion (0, 1–4, and >4 units) were significantly different in terms of diagnosis, age, gender, body mass index, mean pulmonary artery pressure, lung allocation score, hemoglobin, prior chest surgery, preoperative hospitalization, and extracorporeal membrane oxygenation requirement. Inverse probability treatment weighting logistic regression showed that intraoperative PRBC transfusion of >4 units was significantly (P < 0.001) associated with grade 3 PGD within 72 h (odds ratio [95% confidence interval], 2.2 [1.6-3.1]). Inverse probability treatment weighting analysis excluding patients with extracorporeal membrane oxygenation support produced similar findings (odds ratio [95% confidence interval], 2.4 [1.7-3.4], P < 0.001). Conclusions. In this multicenter, international registry study of LT patients, intraoperative transfusion of >4 units of PRBCs was associated with an increased risk of grade 3 PGD within 72 h. Efforts to improve post-LT outcomes should include perioperative blood conservation measures.
Changes in Cardiovascular Health Across Midlife and Late-Life and Magnetic Resonance Imaging Markers of Cerebral Vascular Disease in Late-Life
Sedaghat, Sanaz , Ji, Yuekai, Empana, Jean‐Philippe , Hughes, Timothy M. , Mosley, Thomas H. , Griswold, Michael , Jack, Clifford R. , Lutsey, Pamela L. , Mosley, Thomas H. , Gottesman, Rebecca F , Jack, Clifford R , Lutsey, Pamela L , van Sloten, Thomas T , Gottesman, Rebecca F.

Mayo Clinic

Stroke | March 23, 2023 | Volume: 54 | Issue: 5 | Pages: 1280-1288

10.1161/strokeaha.122.041374 | PMID 36951053 Get It

Background: Cardiovascular health may be used for prevention of cerebral vascular disease; however, data on the association of cardiovascular health across midlife and late-life with late-life cerebral vascular disease are lacking. Our aim was to examine whether midlife or late-life cardiovascular health as well as changes of cardiovascular health within midlife and between midlife and late-life were associated with prevalence of magnetic resonance imaging markers of cerebral vascular disease at late-life. Methods: Prospective cohort study including 1638 participants from the Atherosclerosis Risk in Communities Study who took part in 2 visits at midlife (mean ages, 53 and 59 years), and a late-life visit (mean age, 76 years). A cardiovascular health Life’s Simple 7 score (range, 0–12/0–14, depending on diet availability) including 6 out of 7 items was calculated at each visit, with weight assigned to each item as poor (0), intermediate (1), or ideal (2). Participants underwent 3T brain magnetic resonance imaging scans in late-life visit. Outcomes were white matter hyperintensity volume, microbleeds, and lacunar, subcortical, and cortical infarcts at late-life. Linear and logistic regression models were used to assess the associations of cardiovascular health in midlife and late-life, and improvement of cardiovascular health within midlife, and from midlife to late-life with magnetic resonance imaging markers of cerebral vascular disease, adjusting for potential confounders. Results: A higher cardiovascular health in midlife, improvement of cardiovascular health within midlife, higher cardiovascular health at late-life, and improvement of cardiovascular health from midlife to late-life were associated with a lower prevalence of cerebral vascular disease markers. For example, improvement in cardiovascular health (per point) from midlife to late-life was associated with smaller white matter hyperintensity volume (β, −0.07 [95% CI, −0.10 to −0.04]) and lower odds of microbleeds (odds ratio, 0.93 [0.90–0.97]), lacunar (odds ratio, 0.93 [0.89–0.97]), subcortical (odds ratio, 0.93 [0.89–0.97]), and cortical infarcts (odds ratio, 0.92 [0.87–0.97]). Conclusions: Improving cardiovascular health within midlife and from midlife to late-life may prevent development of cerebral vascular disease.
Algorithm development to improve intervention effectiveness for parents with mental health signs and symptoms
Austin, Robin , Laarhoven, Elizabeth Van, Hjerpe, Anna C., Huling, Jared D. , Mathiason, Michelle A. , Monsen, Karen A. , Austin, Robin R , Van Laarhoven, Elizabeth, Graefe, Anna

Mayo Clinic

Public Health Nursing | March 21, 2023 | Volume: 40 | Issue: 4 | Pages: 556-562

10.1111/phn.13190 | PMID 36943178 Get It

AbstractObjectivesIn this study we aimed to describe and compare groups formed by a rules‐based algorithm to prospectively identify clients at risk of poor outcomes in order to guide tailored public health nursing (PHN) intervention approaches.DesignData‐driven methods using standardized Omaha System PHN documentation.SampleClients ages 13–40 who received PHN home visiting services for both the Caretaking/parenting and Mental health problems (N = 4109).MeasurementWe applied a theory‐based algorithm consisting of six rules using existing Omaha System data. We examined the groups formed by the algorithm using standard descriptive, inferential statistics, and Latent Class Analysis.ResultsClients (N = 4109) were 25.1 (SD = 5.9) years old and had an average of 7.3 (SD = 3.2) problems, 250 (SD = 319) total interventions, and 32 (SD = 44) Mental health interventions. Overall outcomes improved after PHN interventions (p < .001 for all) and having more Mental health signs/symptoms was negatively associated with outcome scores (p < .001 for all).ConclusionsThis algorithm may be helpful in identifying high‐risk clients during a baseline assessment who may benefit from more intensive mental health interventions. Findings show there is value using the Omaha System for PHN documentation and algorithm clinical decision support development. Future research should focus on algorithm implementation in PHN clinical practice.
Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts
Dickow, Jannis , Kany, Shinwan , Cardoso, Victor Roth , Gkoutos, Georgios V. , Houten, Holly K. Van , Kirchhof, Paulus , Metzner, Andreas , Noseworthy, Peter A. , Yao, Xiaoxi , Rillig, Andreas , Roth Cardoso, Victor , Ellinor, Patrick T , Gkoutos, Georgios V , Van Houten, Holly K , Kirchhof, Paulus , Noseworthy, Peter A , Yao, Xiaoxi , Rillig, Andreas , Ellinor, Patrick T.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | March 21, 2023 | Volume: 16 | Issue: 5 | Pages: No page available

10.1161/circep.122.011585 | PMID 36942567 Get It

Background: A recent subanalysis of the EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) suggests a stronger benefit of early rhythm control (ERC) in patients with atrial fibrillation and a high comorbidity burden when compared to patients with a lower comorbidity burden. Methods: We identified 109 739 patients with newly diagnosed atrial fibrillation in a large United States deidentified administrative claims database (OptumLabs) and 11 625 patients in the population-based UKB (UK Biobank). ERC was defined as atrial fibrillation ablation or antiarrhythmic drug therapy within the first year after atrial fibrillation diagnosis. Patients were classified as (1) ERC and high comorbidity burden (CHA 2 DS 2 -VASc score ≥4); (2) ERC and lower comorbidity burden (CHA 2 DS 2 -VASc score 2–3); (3) no ERC and high comorbidity burden; and (4) no ERC and lower comorbidity burden. Patients without an elevated comorbidity burden (CHA 2 DS 2 -VASc score 0–1) were excluded. Propensity score overlap weighting and cox proportional hazards regression were used to balance patients and compare groups for the primary composite outcome of all-cause mortality, stroke, or hospitalization with the diagnoses heart failure or myocardial infarction as well as for a primary composite safety outcome of death, stroke, and serious adverse events related to ERC. Results: In both cohorts, ERC was associated with a reduced risk for the primary composite outcome in patients with a high comorbidity burden (OptumLabs: hazard ratio, 0.83 [95% CI 0.72–0.95]; P =0.006; UKB: hazard ratio, 0.77 [95% CI, 0.63–0.94]; P =0.009). In patients with a lower comorbidity burden, the difference in outcomes was not significant (OptumLabs: hazard ratio, 0.92 [95% CI, 0.54–1.57]; P =0.767; UKB: hazard ratio, 0.94 [95% CI, 0.83–1.06]; P =0.310). The comorbidity burden interacted with ERC in the UKB (interaction- P =0.027) but not in OptumLabs (interaction- P =0.720). ERC was not associated with an increased risk for the primary safety outcome. Conclusions: ERC is safe and may be more favorable in a population-based sample of patients with high a comorbidity burden (CHA 2 DS 2 -VASc score ≥4).